Home About Team Portfolio Investors News Contact Welcome to SV Life Sciences SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco. SV Life Sciences News Entellus Medical - IPO - January 2015 SV Life Sciences Advisers notes that Entellus Medical successfully listed on NASDAQ on 29 January 2015 The business wire press release is below Nasdaq Welcomes Entellus Medical, Inc. (Nasdaq: ENTL) to The Nasdaq Stock Market NEW YORK, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company, commenced on The Nasdaq Stock Market on January 29, 2015. » Read Full Article Sale of Convergence Pharmaceuticals - January 2015 SV Life Sciences Fund V notes that Biogen Idec (NASDAQ: BIIB) acquired Convergence from its owners, SV Life Sciences and others, for a possible total of $ 675m - $200m upfront and $475m of milestone based payments. Convergence Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for chronic pain. » Read Full Article Home | About | Team | Portfolio | Investors | News | Legal | Contact In the UK, SV Life Sciences Advisers LLP (registered in England OC 308830, VAT 852 5150 39) is authorised and regulated by the Financial Conduct Authority ('FCA'). It is entered into the FCA's register and with registration number 409123. The registered office is 71 Kingsway, London, WC2B 6ST.